Firoozeh Sahebi

Firoozeh Sahebi, M.D.

  • Associate Clinical Professor, Department, Hematology & Hematopoietic Cell Transplantation

Firoozeh Sahebi, M.D.

Clinical Specialties
  • Hematologist/Oncologist
Areas of Expertise
  • Bone marrow transplantation
Firoozeh Sahebi, M.D., is a board-certified hematologist specializing in bone marrow transplants. She is also a member of the City of Hope/Kaiser Bone Marrow Transplantation Team.

Dr. Sahebi was trained in medicine at the University of Tehran, then completed her internship and residency in internal medicine at Nassaui University Medical Center in East Meadow, NY. She completed two fellowships, one in hematology/oncology at Columbia University, and the other in hematology/oncology at the UCLA Medical Center.
 
  • 1998-present, Associate Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 1994-present, Staff Physician, Division of Bone Transplantation and Hematology/Oncology, Kaiser Hospital, Los Angeles, CA

Locations

Duarte

1500 East Duarte Road, Duarte, CA, 91010

Get Directions

Phone :  626-256-4673

Degrees

  • 1987, M.D., Tehran University, School of Medicine, Tehran, Iran

Fellowship

  • 1992-1994, Divisions of Hematology /Oncology, UCLA Medical Center, Los Angeles, CA
  • 1991-1992, Divisions of Hematology/ Oncology, Columbia University, College of Physicians & Surgeons, Presbyterian Hospital, New York, NY

Residency

  • 1989-1991, Nassau County Medical Center, State University of New York at Stony Brook, New York, NY

Internship

  • 1988-1989. Nassau County Medical Center, State University of New York at Stony Brook, New York, NY
  • American Board of Internal Medicine, Diplomat
  • American Board of Oncology, Board of Hematology
  • Garderet L, Cook G, Auner HW, Bruno B, Lokhorst H, Perez-Simon JA, Sahebi F, Scheid C, Morris C, van Biezen A, Sobh M, Michallet M, Gahrton G, Schonland S, Kroger N. Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting. Leuk Lymphoma. 2016 Sep 21:1-12. [Epub ahead of print] PMID: 27650125
  • Nomura JH, Eichhorn K, Cao TM, Sahebi F. Cytomegalovirus (CMV) sinusitis complicated by orbital apex syndrome in an immunocompromised host. Transpl Infect Dis. 2016 Sep 28. DOI: 10.1111/tid.12616. [Epub ahead of print] PMID:27677910
  • D'Souza A, Pasquini M, Logan 8, Giralt S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K, Sahebi F, Weisdorf D, Vesole D, Stadtmauer E, Maloney D, Hari P. Heavy/fight chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. Br J Haematol. 2016 Jun 13. DOI: 10.1111/bjh.14170. [Epub ahead of print] PMID:27292583
  • Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma._Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-40. DOI: 10.1016/j.bbmt.2015.07.018. Epub 2015 Jul 26. PMID:26211987; PMC4639410
  • Sahebi F, Iacobelli S, Biezen AV, Volin L, Dreger P, Michallet M, Ljungman PT, de Witte T, Henseler A, Schaap NP, Lopez-Corral L, Poire X, Passweg J, Hamljadi RM, Thomas SH, Schonland S, Gahrton G, Morris C, Kroger N, Garderet L. Comparison of upfront tandem autologous-a/logeneic transplantation versus reduced intensity a/logeneic transplantation for multiple myeloma. Abstract, Bone Marrow Transplant. 2015Jun;50(6):802-7. DOI: 10.1038/bmt.2015.45. Epub 2015 Mar 23. PMID:25798673
  • Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McsweeneyPA,Maris MB, Maziarz RT, Langston AA, Bethge W, Vindel121v L, Franke GN, Laport GG, Yeager AM, Hubel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM. Graft-versus-host disease and graft-versus­tumor effects after al/ogeneic hematopoietic cell transplantation. J Clin Oneel. 2013 Apr 20;31(12):1530􀂴8. DOI: 10.1200/JCO.2012.45.0247. Epub 2013 Mar 11. PMIO: 23478054; PMC3625710
  • Sahebi F, Shen Y, Thomas SH, Rincon A, Murata-Collins J, Palmer J, Krishnan AY, Karanes C, Htut M, Somlo G, Forman SJ. Late relapses following reduced intensity al/ogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. Br J Haematol. 2013 Jan;160(2):199-206. DOI: 10.1111/bjh.12123. Epub 2012 Nov 15. PMID: 23151215; PMCID:3542410
  • Krishnan AY, Mei M, Sun CL, Thomas SH, Teh JB, Kang T, Htut M, Somlo G, Sahebi F, Forman SJ, Bhatia S. Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2013 Feb;19(2):260-5. DOI:10.1016/j.bbmt.2012.09.023. Epub 2012 Oct 13. PMID: 23073267; PMCID: PMC3553262.
Back To Top